Treatment in first line of mantle cell lymphoma for patients under 66 Years by the VAD [vincristine + doxorubicin + dexamethasone] -chlorambucil -rituximab regimen followed by intensification and autologous PBSC [Peripheral blood stem cell] transplantation after marrow purging with rituximab

Trial Profile

Treatment in first line of mantle cell lymphoma for patients under 66 Years by the VAD [vincristine + doxorubicin + dexamethasone] -chlorambucil -rituximab regimen followed by intensification and autologous PBSC [Peripheral blood stem cell] transplantation after marrow purging with rituximab

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Rituximab (Primary) ; Chlorambucil; Dexamethasone; Doxorubicin; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 31 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top